A carregar...
Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study
BACKGROUND: The relative efficacy of lapatinib vs. continuing trastuzumab beyond progression (TBP) in HER2-positive metastatic breast cancer (MBC) patients, who progressed on first-line trastuzumab, is still unclear. The objective of this population based cohort study was to compare outcomes of lapa...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4574060/ https://ncbi.nlm.nih.gov/pubmed/26375590 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0138229 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|